(CercleFinance.com) – Biogen announces plans to reprioritize its resources in Alzheimer’s disease (AD), where it will continue to advance its Leqembi and accelerate the development of potential treatment modalities, including BIIB080 and BIIB113 .
The group will, however, end the development and marketing of Aduhelm injectable at 100 mg/mL for intravenous use, as well as the Envision clinical study, a decision which is not linked to safety issues or efficiency.
Biogen recorded a one-time charge of approximately $60 million related to the costs of closing this program in the fourth quarter of 2023. A large portion of the resources thus freed will be redeployed in its AD franchise.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
